Clinical trials: Hepatobiliary Disorders
Hepatic Impairment, Healthy Participants
A STUDY TO COMPARE THE PHARMACOKINETICS OF PF-06835919 IN PARTICIPANTS WITH AND WITHOUT HEPATIC IMPAIRMENT
The study is proposed to characterize the effect of varying degrees of hepatic impairment on the plasma PK of PF-06835919
- Trial name
- NCT04193436
- Testing
- PF-06835919 25 mg
- Where
- 3 sites in Belgium, Czechia and 1 more
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Pfizer
Nonalcoholic Steatohepatitis (NASH)
Safety and Effectiveness of BMS-986263 in Adults With Compensated Cirrhosis (Liver Disease) From Nonalcoholic Steatohepatitis (NASH)
The purpose of this randomized study is to assess safety and effectiveness of BMS-986263 in adults with compensated cirrhosis (chronic liver disease) from nonalcoholic steatohepatitis (fatty liver disease) (NASH).
- Trial name
- NCT04267393
- Testing
- BMS-986263
- Where
- 112 sites in United States, Argentina and 14 more
- Volunteers
- 124 people
- Sponsor
- Bristol-Myers Squibb
Liver Diseases, Alcoholic
A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease
The goal of this study is to assess the safety and efficacy of GSK4532990 in participants with alcohol-related liver disease.
- Trial name
- STARLIGHT (NCT06613698)
- Testing
- GSK4532990
- Where
- 140 sites in United States, Argentina and 16 more
- Volunteers
- 393 people
- Sponsor
- GlaxoSmithKline
Non-Alcoholic Fatty Liver Disease
Combining MRI Steatosis Assessment and Transient Elastography to Improve Liver Fibrosis Diagnosis in Non Alcoholic Fatty Liver Disease
The main objective is to compare the accuracy of transient elastography taking into account liver steatosis determined by MRI, to liver biopsy for the diagnosis of liver fibrosis ≥F2 in patient with NAFLD.
- Trial name
- FibroMR (NCT03245606)
- Testing
- Liver biopsy, Abdominal MRI, Transient elastography
- Where
- 9 sites in France
- Volunteers
- 270 people
- Sponsor
- Rennes University Hospital
Patient Engagement
Impact of Teach Back of Discharge Information in Term of Patient Recall of Information and Patient Engagement
Impact of Teach Back of Discharge Information in term of patient Recall of Information and patient Engagement in self-care among Chronic Liver Disease patients admitted in selected wards of ILBS, New Delhi Primary objectives 1.
- Trial name
- NCT05280171
- Testing
- Teach back, Standard of care
- Where
- India
- Volunteers
- 60 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Malignant Neoplasm, Leukemia, Lymphocytic, Chronic, B-Cell
Project to Improve Communication About Serious Illness - Pilot Study
This two-year pilot study will test whether a one-page "Jumpstart Form" will affect goals-of-care discussions in the hospital. This form will be provided to clinicians and will include patient-specific information about…
- Conditions
- Malignant Neoplasm, Leukemia, Lymphocytic, Chronic, B-Cell, Lung Disease Chronic, Congestive Heart Failure
- Trial name
- PICSI-P (NCT03746392)
- Testing
- Jumpstart Intervention
- Where
- 2 sites in United States
- Volunteers
- 150 people
- Sponsor
- University of Washington
Fatty Liver, Nonalcoholic
Lifestyle Changes in Fatty Liver; Additive Effect of Honey Intake
honey is a natural functional food used in control cardiovascular risk factors but its effect on fatty liver is not investigated
- Trial name
- NCT06596109
- Testing
- honey intake and lifestyle changes, lifestyle changes
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Cairo University
Metabolic Syndrome (MetS), Obesity & Overweight
Validating Integrative Multi-omics Approaches in Metabolic Syndrome-related Diseases
This study aims to validate integrative multi-omics approaches for understanding complications related to metabolic syndrome. By combining genetic, transcriptomic, metabolomic, and microbiome data from participants with and…
- Conditions
- Metabolic Syndrome (MetS), Obesity & Overweight, Cardiovascular Diseases (CVD), Chronic Kidney Disease
- Trial name
- NCT07248371
- Testing
- No intervention
- Where
- Taiwan
- Volunteers
- 6,266 people
- Sponsor
- Chang Gung Memorial Hospital
Obesity, Metabolic Dysfunction-associated Steatotic Liver Disease
ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver Disease
This study is for adults aged 18 years and older who have a type of fatty liver disease called metabolic dysfunction-associated steatotic liver disease (MASLD).
- Trial name
- NCT07850063
- Testing
- Survodutide
- Where
- 34 sites in United States, China and 3 more
- Volunteers
- 600 people
- Sponsor
- Boehringer Ingelheim
NAFLD, NASH - Nonalcoholic Steatohepatitis
Vitamin E for NASH Treatment in HIV Infected Individuals
The purpose of this study is to see how taking Vitamin E daily affects fatty liver in persons living with HIV. Subjects will have both HIV and a fatty liver and the purpose of the study is to learn if underlying liver condition…
- Conditions
- NAFLD, NASH - Nonalcoholic Steatohepatitis, HIV Infections
- Trial name
- NCT03669133
- Testing
- Vitamin E
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Indiana University
NAFLD, Diabete Type 2
The Improvement Effect of Henggliejin on Fatty Liver in Type 2 Diabetes Patients With Nonalcoholic Fatty Liver:
To evaluate the effect and safety of Henggliejin on fatty liver in type 2 diabetes patients with nonalcoholic fatty liver disease
- Trial name
- NCT07198516
- Testing
- Addition of Hengge Liejing treatment for 48 weeks
- Volunteers
- 149 people
- Sponsor
- Fujian Medical University Union Hospital
Alagille Syndrome, Cholestasis
Study of Magnesium Sulfate in Children With Reduced Bone Density Secondary to Chronic Cholestatic Liver Disease
OBJECTIVES: I. Determine the role of magnesium deficiency in the pathogenesis of decreased serum vitamin D and reduced bone density in children with chronic cholestatic liver disease.
- Conditions
- Alagille Syndrome, Cholestasis, Biliary Atresia
- Trial name
- NCT00007033
- Testing
- magnesium gluconate, magnesium sulfate
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Center for Research Resources (NCRR)
Underlying Liver Disease, Hepatitis
Rapid 10-Minute Liver MRI Protocol in Patients With Suspected Hepatocellular Carcinoma
The purpose of this study to assess the image quality of the rapid magnetic resonance imaging (MRI) compared to the standard MRI.
- Conditions
- Underlying Liver Disease, Hepatitis, Fibrosis of Liver, Cirrhosis With Suspicion of Liver Cancer
- Trial name
- NCT01390194
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Nebraska
Inpatient With End Stage Liver Disease
Is Access to Liver Transplantation Similar in Alcoholic or Not Patients?
The purpose of this study is to determine whether there are reasons other than medical reasons that could limit access to liver transplantation in alcoholic patients.
- Trial name
- TRANSALC (NCT01820819)
- Where
- France
- Volunteers
- 574 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
HIV Infections, Non-Alcoholic Fatty Liver Disease
Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study)
The purpose of this study was to evaluate the effects of semaglutide on intra-hepatic triglyceride (IHTG) content in people living with HIV (PLWH), central adiposity, insulin resistance or pre-diabetes, and hepatic steatosis.
- Trial name
- NCT04216589
- Testing
- Semaglutide
- Where
- 9 sites in United States, Brazil
- Volunteers
- 51 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Metabolic Dysfunction-associated Liver Disease
Effect of Plant-based Diets on Liver Biomarkers, Cardiometabolic Health, and Exposure to Environmental Contaminants and Endocrine Disruptors in Patients With Metabolic Liver Disease.
Plant-based diets have gained increasing recognition for their sustainability and their benefits on cardiometabolic and liver health.
- Trial name
- ESTEATOVEG (NCT07503431)
- Testing
- Traditional Mediterranean diet, Vegan Mediterranean diet
- Where
- Spain
- Volunteers
- 50 people
- Sponsor
- Miguel López Moreno
Hepatitis
Severe Hepatitis Intervention With Emapalumab for Liver Disease
The goal of this study is to see whether a medicine called emapalumab, a monoclonal antibody, is safe and works well for patients aged 1 year and older who have indeterminate severe hepatitis with T-cell activation and have not…
- Trial name
- SHIELD (NCT07744919)
- Testing
- Emapalumab
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Children's Healthcare of Atlanta
Decompensated Cirrhosis, Small Bowel Bacterial Overgrowth Syndrome
Primary Prophylaxis for Spontaneous Bacterial Peritonitis
Patient with liver cirrhosis commonly have co-existing small bowel bacterial overgrowth (SIBO) yet may be asymptomatic. It is unclear as to the value of treating SIBO in asymptomatic individuals.
- Trial name
- SIBOC (NCT04775329)
- Testing
- Rifaximin
- Where
- Singapore
- Volunteers
- 2 people
- Sponsor
- Changi General Hospital
Compensated Advanced Chronic Liver Disease
CHESS-SAVE Score to Stratify Decompensation Risk in Compensated Advanced Chronic Liver Disease (CHESS2102)
Compensated advanced chronic liver disease (cACLD) was associated with a high rate of variceal bleeding, ascites, and hepatic encephalopathy due to portal hypertension.
- Trial name
- NCT04975477
- Testing
- Esophagogasrtoduodendoscopy and liver stiffness, hepatic venous pressure gradient
- Where
- 7 sites in China, Egypt and 3 more
- Volunteers
- 1,000 people
- Sponsor
- Hepatopancreatobiliary Surgery Institute of Gansu Province
Nonalcoholic Steatohepatitis
Study of SGM-1019 in Patients With Nonalcoholic Steatohepatitis (NASH)
This is a multicenter, randomized, double-blind, placebo-controlled study evaluating the safety, pharmacokinetics, and pharmacodynamics of 12 weeks' administration of SGM-1019 in subjects with fibrosis stage 1-3 (F1-F3) NASH.
- Trial name
- NCT03676231
- Testing
- SGM-1019
- Where
- 10 sites in United States
- Volunteers
- 9 people
- Sponsor
- Second Genome
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.